E4CPG

Research use only, not for human use.

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

E4CPG acts at rat cortical mGluR with the KB value of 0.367 mM.

E4CPG (3-30 nmol/site (i.t.), 1-10 μmol/paw(i.pl.), and 1-10 nmol/site (i.c.v.)) significantly inhibits the nociception induced by the Glutamate-injection (i.pl.; 30 μmol/paw), and the maximal inhibition valuesfor the antinociceptive action of E4CPG in Glutamate-induced nociception are 48% (i.pl.),49% (i.t.) and 40% (i.c.v.) . E4CPG (35 nM/3.5 μL, i.c.v.) completely blocks long-term depression (LTD) induced by the group I mGluR agonist Dihydroxyphenylglycine (DHPG, 100 nM/5 μL, i.c.v.) in male Sprague-Dawley rats. Animal Model:Male Swiss mice (25-35 g) Dosage:3-30 nmol/site (i.t.), 1-10 μmol/paw(i.pl.) and 1-10 nmol/ site (i.c.v.)Administration:Single injectionResult:The maximal inhibition values for the antinociceptive action of E4CPG in glutamate-induced nociception were 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.).Animal Model:Male Sprague-Dawley rats Dosage:35 nM/3.5 μL Administration:Single injection, i.c.v.Result:Completely blocked LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG).

——

Angiogenesis

EGFR

mGluR

Cancer

——

170846-89-6

223.23

C11H13NO4

>98% (HPLC)

DMSO : < 1 mg/mL

C(=O)(c1ccc(cc1)C(CC)(C(=O)O)N)O

——

(-20℃)

With Ice Pack

≥ 2 years